Medical Guidance Systems

Medical Guidance Systems (MGS) is a biotechnology company focused on developing next-generation cancer immunotherapies and nanotechnology-enabled drug delivery systems. Founded in 2013 based on the research of Dr. Dennis Hallahan at Washington University in St. Louis, the company targets radiation-inducible neo-antigens that are overexpressed on cancer cells following radiotherapy. MGS's proprietary platforms, including Ligand Directed and Antibody Directed approaches, aim to deliver therapeutic payloads, imaging agents, or radiosensitizing drugs specifically to tumor sites. Its lead preclinical pipeline includes monoclonal antibodies and antibody-drug conjugates (ADCs) targeting stress-regulated proteins like TIP1 and GRP78 to enhance the efficacy of radiation therapy in poor-prognosis cancers such as non-small cell lung cancer and glioblastoma.